194. Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
Session: Poster Abstract Session: Clinical: Bone and Joint Infection
Thursday, October 5, 2017
Room: Poster Hall CD
Posters
  • Sims_IDWeek 2017 Bone and Joint Poster_Final layout_26Sep17.pdf (1.7 MB)
  • Background: Telavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA). Bone and joint infections represent a complex set of diseases requiring prolonged antimicrobial therapy and are commonly caused by Gram-positive pathogens, including S. aureus.

    Methods: The Telavancin Observational Use Registry (TOUR™) is a multicenter chart review study designed to characterize infection types, pathogens, and outcomes of patients treated with TLV in clinical practice. Data from TOUR were used to characterize a subset of bone and joint patients. Clinical data including patient demographics, pathogens, outcomes, and adverse events (AEs) were analyzed. Clinical outcomes were determined by investigators’ assessment.

    Results: As of March 31, 2017, data for more than 1000 patients were collected from 46 sites. Of these, 286 patients were treated for bone and joint infections. Among these 286 patients, median age was 57 years (range 18−92 years) and 27% (n = 76) were aged ≥65 years, 66% (n = 189) were male, and 84% (n = 241) were White. The median body mass index was 30.0 kg/m2 (range 19.2−62.7 kg/m2). MRSA was the most commonly isolated pathogen at baseline (38%; n = 108). The median TLV daily dose and duration of treatment were 750 mg (range 300−1500 mg) or 8.3 mg/kg (range 3.7−16.9 mg/kg) and 26.5 days (range 1−119 days), respectively. Telavancin was used as second-line therapy in 71% (n = 202) of patients, and the majority of patients (66%; n = 189) were treated as outpatients. Overall, 71% (n = 203) of patients were cured or improved to step-down therapy, 9% (n = 25) failed treatment, 10% (n = 30) had an indeterminate clinical outcome at end of therapy (EOT), and 10% (n = 28) had missing or undocumented outcomes. Among the patients who had outcome assessment (n = 258) at EOT, 79% were cured or improved to step-down therapy and 10% failed therapy. AEs were reported in 45 patients; 6 reported a serious AE, and 32 had AEs leading to TLV discontinuation.

    Conclusion: In a real-world setting, once-daily TLV produced a positive clinical response in >70% of patients with difficult-to-treat bone and joint infections and may represent an alternative treatment option.

    Charles Sims, MD1, Adam Bressler, MD2, Melinda Lacy, PharmD3, Anna Osmukhina, PhD3 and Bibiana Castaneda-Ruiz, MD3, (1)University of Texas Medical School - Houston, Houston, TX, (2)Infectious Disease Specialists of Atlanta, Decatur, GA, (3)Theravance Biopharma US, Inc., South San Francisco, CA

    Disclosures:

    C. Sims, Theravance Biopharma US, Inc.: Investigator and Speaker's Bureau , Research grant , Research support and Speaker honorarium

    A. Bressler, Theravance Biopharma US, Inc.: Investigator , Scientific Advisor , Shareholder and Speaker's Bureau , Consulting fee , Research support and Speaker honorarium

    M. Lacy, Theravance Biopharma US, Inc.: Employee , Salary

    A. Osmukhina, Theravance Biopharma US, Inc.: Employee and Shareholder , RSU, Stock Options and Salary

    B. Castaneda-Ruiz, Theravance Biopharma US, Inc.: Employee and Shareholder , Salary

    Previous Abstract | Next Abstract >>

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.